Skip to Main Content

Paper Details

Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
ESMO Open
5
2022
Author NameAffiliation
Jes??s Garc??a-DonasClara Campal Comprehensive Cancer Center
  • 1 - 1

Datasets

Release 1.2